Heart Disease Stem Cell Treatments

HEART (CARDIAC) DISEASE

Heart disease is a leading cause of morbidity and death. With Americans often having a poor diet leading to obesity and metabolic syndrome the trend to heart disease continues in the U.S.A. Patients that have had a history of heart failure, myocardial infarction, enlarged heart due to cardiomyopathy, previous history of bypass cardiac surgery or stents and reports of a “low ejection fractions” should consider stem cell treatment.

We request lab reports of the patient’s cardiac enzymes, cholesterol, triglycerides, HDL, LDL; reports of the echocardiogram and stress echocardiogram, EKG and Holter monitor for evaluating cardiac rhythm.

Treatment by StemCellRegenMed consists of the following:

Stimulation of the patient’s own stem cell niches in the heart with oral and injectable agents.
Autologous stem cells taken from patient’s bone marrow or peripheral blood.
Cardiac stem cell precursors (cardiomyocytes) extracted from umbilical cord blood; precursor CD 34+ and CD 133+ cells mixed with stem cell factor and at times mixed with a specific antibody that promotes the engraftment of the stem cells into heart muscle (myocardium).

The stem cells can be administered intravenously which migrate only to the damaged heart muscle. The survival of these stem cells is assisted by the co-administration of stem cell factor and vascular endothelial growth factor. We recommend initially the above non-invasive approach. The patient is followed and tested regularly over the next six months.

Only if there is insufficient cardiac improvement measured by ejection fraction that the patient would get a repeat treatment of the cardiac stem cells but this time administered through cardiac catherization to the aortic arch.
The patient will be on a cardiac rehabilitation program supervised by a cardiologist. In addition continued stimulation of cardiac stem cell niches with oral and injectable agents as well as the transplanted cardiomyocytes will continue for the next six months or longer.

Medical Disclaimer: Treatments discussed on this website are experimental and have not been approved by the FDA. No guarantees are made regarding the results of these treatments. Prospective patients are advised to discuss the use of a Stem Cell treatment for their disease with their physician.


		HEART (CARDIAC) DISEASE Heart disease is a leading cause of morbidity and death. With Americans often having a poor diet leading to obesity and metabolic syndrome the trend to heart disease continues in the U.S.A. Patients that have had a history of heart failure, myocardial infarction, enlarged heart due to cardiomyopathy, previous history of bypass cardiac surgery or stents and reports of a “low ejection fractions” should consider stem cell treatment. We request lab reports of the patient’s cardiac enzymes, cholesterol, triglycerides, HDL, LDL; reports of the echocardiogram and stress echocardiogram, EKG and Holter monitor for evaluating cardiac rhythm. Treatment by StemCellRegenMed consists of the following: Stimulation of the patient’s own stem cell niches in the heart with oral and injectable agents. Autologous stem cells taken from patient’s bone marrow or peripheral blood. Cardiac stem cell precursors (cardiomyocytes) extracted from umbilical cord blood; precursor CD 34+ and CD 133+ cells mixed with stem cell factor and at times mixed with a specific antibody that promotes the engraftment of the stem cells into heart muscle (myocardium). The stem cells can be administered intravenously which migrate only to the damaged heart muscle. The survival of these stem cells is assisted by the co-administration of stem cell factor and vascular endothelial growth factor. We recommend initially the above non-invasive approach. The patient is followed and tested regularly over the next six months. Only if there is insufficient cardiac improvement measured by ejection fraction that the patient would get a repeat treatment of the cardiac stem cells but this time administered through cardiac catherization to the aortic arch. The patient will be on a cardiac rehabilitation program supervised by a cardiologist. In addition continued stimulation of cardiac stem cell niches with oral and injectable agents as well as the transplanted cardiomyocytes will continue for the next six months or longer. Medical Disclaimer: Treatments discussed on this website are experimental and have not been approved by the FDA. No guarantees are made regarding the results of these treatments. Prospective patients are advised to discuss the use of a Stem Cell treatment for their disease with their physician.